Viridian Therapeutics Q4 revenue misses analyst expectations

Reuters02-26
Viridian <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 revenue misses analyst expectations

Overview

  • Biotechnology firm's Q4 revenue missed analyst expectations

  • Net loss for Q4 widened compared to last year

  • Company maintains strong cash position, expects to fund plans through profitability

Outlook

  • Viridian expects veligrotug's U.S. commercial launch in mid-2026, pending FDA approval

  • Company anticipates elegrobart topline data in Q1 and Q2 2026

  • Viridian plans to fund business plans through profitability with cash and potential revenues

Result Drivers

  • R&D EXPENSES - Increase driven by ongoing clinical trials and manufacturing activities for TED portfolio, and advancing FcRn inhibitor portfolio and TSHR program

  • SG&A EXPENSES - Rise due to preparatory commercial activities for veligrotug, including increased personnel costs

  • CASH POSITION - Strong cash reserves expected to fund business plans through profitability

Company press release: ID:nBw7mLxhNa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Miss

$132,000

$12.73 mln (13 Analysts)

Q4 Net Income

-$120.36 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Viridian Therapeutics Inc is $42.00, about 45.1% above its February 25 closing price of $28.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment